Literature DB >> 26707367

Systematic Review and Meta-Analysis: Macrolides- and Amoxicillin/Clavulanate-induced Acute Liver Injury.

Pili Ferrer1, Justyna Amelio2, Elena Ballarín1,3,4, Mònica Sabaté1,3,4, Xavi Vidal1,3,4, Marietta Rottenkolber5, Sven Schmiedl6,7, Joan-Ramon Laporte1,3,4, Luisa Ibáñez1,3,4.   

Abstract

Antibacterials are frequently associated with idiosyncratic drug-induced liver injury (DILI). The objective of this study was to estimate the risk of macrolides and amoxicillin/clavulanate (AMC) on DILI. We conducted a systematic review (SR) and meta-analysis (MA) with studies retrieved from PubMed, Cochrane Library Plus, Web of Knowledge, clinicaltrials.gov, Livertox and Toxline (1980-2014). We searched for macrolides, AMC and MeSH and synonym terms for DILI. We included all study designs except case reports/series, all population ages and studies with a placebo/non-user comparator. We summarized the evidence with a random-effects MA. Quality of the studies was appraised with a checklist developed for SR of adverse effects. Heterogeneity and publication bias were assessed with different exploratory tools. We finally included 10 (two randomized clinical trials, six case-control, one cohort and one case-population studies) and 9 (case-population excluded) articles in the SR and MA, respectively. The overall summary relative risk of DILI for macrolides was 2.85 [95% confidence interval (CI) 1.81-4.47], p < 0.0001, I(2) = 57%. Three studies were perceived to be missing in the area of low statistical significance. Year of study and selected exposure window partly explained the variability between studies. For AMC, the risk of DILI was 9.38 (95% CI 0.65-135.41) p = 0.3, I2 = 95%. In conclusion, although spontaneous reports and case series have long established an association between macrolides and AMC with acute liver injury, these SR and MA have assessed the magnitude of this association. The low incidence of DILI and the therapeutic place of these antibiotics might tilt the balance in favour of their benefits.
© 2015 Nordic Association for the Publication of BCPT (former Nordic Pharmacological Society).

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26707367     DOI: 10.1111/bcpt.12550

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  4 in total

1.  A Protective Role of Okadaic Acid in Liver Injury Induced by Amoxicillin.

Authors:  D Li; W Shi; X Lu; Z Liu; S Zhang; Y Sun; W Shi; X Zhu
Journal:  Bull Exp Biol Med       Date:  2022-01-10       Impact factor: 0.804

2.  Previous Drug Exposure in Patients Hospitalised for Acute Liver Injury: A Case-Population Study in the French National Healthcare Data System.

Authors:  Nicholas Moore; Stéphanie Duret; Adeline Grolleau; Régis Lassalle; Vanessa Barbet; Mai Duong; Nicolas Thurin; Cécile Droz-Perroteau; Sinem Ezgi Gulmez
Journal:  Drug Saf       Date:  2019-04       Impact factor: 5.606

3.  Clinical characteristics of 34 COVID-19 patients admitted to intensive care unit in Hangzhou, China.

Authors:  Yi Zheng; Li-Jun Sun; Mi Xu; Jian Pan; Yun-Tao Zhang; Xue-Ling Fang; Qiang Fang; Hong-Liu Cai
Journal:  J Zhejiang Univ Sci B       Date:  2020-05       Impact factor: 3.066

4.  Omadacycline for the Treatment of Severe Chlamydia psittaci Pneumonia Complicated with Multiple Organ Failure: A Case Report.

Authors:  Changquan Fang; Limin Xu; Jiarong Tan; Hongyi Tan; Junhong Lin; Ziwen Zhao
Journal:  Infect Drug Resist       Date:  2022-10-04       Impact factor: 4.177

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.